Start with the decision, not the folder
A second opinion is only as useful as the question attached to it. "Is my treatment right?" is hard to answer from a file. "My paraprotein is rising on this regimen and my doctor has suggested changing it — should we change now, and to what?" gives a haematologist something to work with.
So write the question down before you photocopy anything. Two or three sentences is enough: the current diagnosis, what is being proposed, and what you want tested against it. If several decisions are open — whether to intensify treatment, whether a transplant pathway is relevant, whether a clinical trial should be explored — say so, because a reviewer may need to address them separately.
Keep that statement at the front of everything you send. It also protects you from the common failure mode of a second opinion: a large, unlabelled file that produces a generic reply because nobody could tell what was being asked.
Multiple myeloma is a disease where the trend matters more than any single number. A reviewer reading one set of results cannot see whether the paraprotein is falling, plateauing or climbing. If you can only send a little, send serial results with dates rather than a thick bundle from one week.
The laboratory record: what a reviewer needs to see
Myeloma assessment rests on blood and urine tests that are repeated over time, so the value of your file lies in the series. Ask your treating centre for results with the collection date on each report, not just the printout date.
The core items are the full blood count, renal function and calcium, albumin, and the paraprotein measurements — serum protein electrophoresis with immunofixation, serum free light chains, and 24-hour urine electrophoresis where that has been done. Beta-2 microglobulin and lactate dehydrogenase usually appear in the same records. If your centre reports a serum viscosity or other specialised assay, include it.
Where the reports exist, add any cytogenetic and molecular results from bone marrow testing, because these influence how a haematologist thinks about risk and regimen choice. Do not worry about interpreting them yourself; the reviewing clinician will. What matters is that the actual report is legible and complete, including the reference ranges used by the laboratory that performed the test.
One practical point: laboratories differ in units and assay methods. A reviewer comparing your results with a new centre's tests needs to know which laboratory produced each number. Keep the header page of each report rather than cropping to the results table.
Bone marrow, imaging and the pathology question
Include the bone marrow biopsy and aspirate reports in full, with the date and the reporting pathologist's conclusions. If plasma cell percentage, flow cytometry or fluorescence in situ hybridisation results are reported separately, gather those too.
Imaging is often where files are thinnest. Skeletal survey reports, low-dose whole-body CT, MRI or PET-CT reports should be included with their dates and the body areas covered. A radiology report without images may be enough for a records-based discussion, but ask the reviewing team whether they want the images themselves on disc; do not assume either way.
Pathology is worth a specific thought. If the original diagnosis was made elsewhere and the slides are available, a reviewing centre may wish to re-examine the marrow or a plasmacytoma specimen. Whether re-review is needed, and whether blocks or slides must be requested from the original hospital, is a question for the receiving clinician — not something you can settle from a checklist.
Ask the original pathology department what it can release and in what form. Requests for slides or blocks can take time to arrange, so raise it early if re-review is a possibility.
Treatment history: the part that is easiest to leave incomplete
A haematologist reading a second-opinion file wants the exact regimen, not the class of drug. "Lenalidomide-based therapy" is less useful than the drug names, doses, cycle dates, start and stop dates, and the reason each line was stopped or changed.
Build a simple table, one row per line of treatment: regimen name and constituent drugs, start date, end date, best response recorded at the time, and reason for stopping — progression, toxicity, completion, patient choice. Add any radiotherapy with site and dates, and any surgery related to myeloma.
Then list supportive medicines that affect myeloma decisions: bisphosphonates or other bone-protective agents, anticoagulation, antivirals used for prophylaxis, steroids, and pain medication. Include allergies and any documented drug reactions, since these constrain what a new team can offer.
If you have had a stem cell collection or transplant, include the date, type and the discharge summary. If transplantation has been discussed but not performed, say so explicitly — a reviewer otherwise cannot tell whether the option was declined, deferred or never raised.
Finally, record your own priorities. Someone who will not accept a particular toxicity profile, or who wants to keep working, is giving the reviewer information that changes the recommendation. Put it in writing rather than hoping it comes up.
How to package and label the file
Order the file the way a clinician reads it: a one-page summary, then the current status, then treatment history, then supporting reports in date order. Number the pages and put your name and date of birth on the summary page only — not on every sheet, and not in an initial web enquiry.
Name electronic files so they can be identified without opening them, for example "2025-03-14 bone marrow report" rather than "scan0042.pdf". If reports are in another language, ask whether a translation is needed and who should provide it; a family member's informal translation may not be accepted for a formal opinion.
Keep a master index listing every document you hold and every document you have requested but not yet received. That index is useful in its own right: it shows the reviewing team where the gaps are, and it stops you from being asked for the same item twice.
For a first contact, send the summary and the question, not the archive. The ChinaSpecialistCare team's free initial review checks the available diagnosis, records and main question, identifies missing information and suggests a next step; it is not a diagnosis and does not promise acceptance. Full records can be shared afterwards through an agreed route.
What a records-based opinion can and cannot settle
A review of documents can comment on whether the recorded diagnosis and staging are coherent, whether the treatment sequence follows recognised pathways, and what options a haematologist would consider discussing. It cannot examine you, and it cannot confirm fitness for a procedure or guarantee that a hospital will accept your case.
That distinction matters for myeloma specifically. Decisions about transplant eligibility, trial enrolment or access to a particular therapy depend on current clinical assessment, local availability and the treating hospital's own judgement. A positive second opinion is a clinical view, not an access decision.
Ask the reviewing clinician directly about the limits: which questions the records can answer, what additional tests they would want, and what would need to happen in person. Clinicians can and should discuss evidence-based risk and expected benefit with you; no estimate guarantees an individual result, so ask what the uncertainty is as well as the headline figure.
If your disease is changing quickly, or you have new pain, fever, confusion or reduced urine output, seek local medical assessment rather than waiting for an overseas opinion. A records review is not an emergency route.
For readers considering care in China, the practical next step is a short enquiry describing the diagnosis, current treatment and the specific decision you want reviewed. An initial enquiry is free and does not require buying a proxy consultation; a proxy consultation is an optional service where a doctor takes records to a relevant hospital specialist for a records-based opinion while you remain at home. The hospital, not the coordinator, decides suitability.
Sources & scope of this guide
References and official service information relevant to this guide.
- radiotherapy
- index
- Related treatment reference
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (Lancet Oncology)
- NCI PDQ treatment summary: Plasma Cell Neoplasms, including multiple myeloma
- IMWG consensus on minimal residual disease assessment in multiple myeloma
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
